Trial Profile

Phase I/IIA Safety and Efficacy Study of IMSA101 in Patients With Advanced Treatment-Refractory Malignancies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 13 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMSA 101 (Primary) ; Antineoplastics
Indications Haematological malignancies; Solid tumours
Focus Adverse reactions
Sponsors ImmuneSensor

Most Recent Events

10 Oct 2023 Status changed from recruiting to completed.
18 Apr 2023 Planned End Date changed from 16 Feb 2023 to 31 Dec 2023.
18 Apr 2023 Planned primary completion date changed from 16 Feb 2023 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com